The Response of Pharmaceutical Manufacturers to the Provisions of the ACA
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The provisions of the Patient Protection and Affordable Care Act of 2010 (the ACA) engendered a number of effects on pharmaceutical manufacturers, including the annual fee, mandated Medicaid drugs rebates, and Medicare prescription drug coverage “donut hole” relief. The authors conduct theoretical and empirical analyses to assess the consequences of the provisions. Both theoretical and empirical analyses show that the provisions have positive correlations with increased prices for branded prescription drugs. These findings reveal that pharmaceutical manufacturers shift drug costs to patients.
Abstract
The provisions of the Patient Protection and Affordable Care Act of 2010 (the ACA) engendered a number of effects on pharmaceutical manufacturers, including the annual fee, mandated Medicaid drugs rebates, and Medicare prescription drug coverage “donut hole” relief. The authors conduct theoretical and empirical analyses to assess the consequences of the provisions. Both theoretical and empirical analyses show that the provisions have positive correlations with increased prices for branded prescription drugs. These findings reveal that pharmaceutical manufacturers shift drug costs to patients.
참고문헌 (25)
- Berndt, E., "Pharmaceuticals in U. S. health care : Determinants of quantity and price", Journal of Economic Perspectives, 16(4), pp.45~66 (2002)
- "Taxing the sick: How “fees” in health care reform hurt patients" (2009)[URL]
- "Fact sheet: 3.6 million in Medicare saved more than $2.1 billion on prescription drugs in the donut hole in 2011" (2012)[URL]
- "Medicaid drug rebate program" (2013)[URL]
- Moral hazard and economies of scope in physician ownership of complementary medical service, "Chen, B.", NBER, ~, pp.NBER Wor king Paper, No. 19622 (2013)
- Deloitte Consulting LLP., "Deloittereview: Moving target-life sciences, health care reform and the new market place, Issue 9", ~ (2011)
- "The express script prescription price index" (2014)[URL]
- Frakt, A., "How much do hospitals cost shift? A review of the evidence", The Milbank Quarterly, 89(1), pp.99~130 (2011)
- Hadley, J., "Hospital cost shifting and care for the uninsured", Health Affairs, 4(3), pp.67~80 (1985)
- Hay, J., "The impact of public health care financing policies on private-sector hospital costs. Journal of Health Politics", Policy and Law, 7(4), pp.945~952 (1983)
- "Health Care Education Affordability Reconciliation Act, Title 1, Subtitle E, §1404, Amending the patient protection and affordable care act" (2010)[URL]
- Internal Revenue Service., "Internal Revenue Code", Notice 2011-92 and 2010-71, ~ (2011)
- Morgan, S., "International best practices for negotiating"reimbursement contracts"with price rebates from pharmaceutical companies", Health Affairs, 32(4), pp.771~776 (2013)
- Morrisey, M., "Cost shifting in health care: Separating evidence from rhetoric" (1994), The AEI Press
- "Patient Protection and Affordable Care Act, 42 U.S.C. § 18001" (2010)[URL]
- Perron, J., "New insurance tax to increase the cost of providing health coverage", Franchising World, 44(2), pp.14~ (2012)
- "Top 50 pharma companies in 2012, by global sales" (2013)[URL]
- "Medicaid drug rebate: Briefing for medicaid health plans of america" (2010)[URL]
- "Preserving Access to Orphan Drugs Act, S. 1128" (2013)[URL]
- Rizzo, J., "Generic script share and the price of brand-name drugs : The role of consumer choice", International Journal of Health Care Finance Economics, 9, pp.291~316 (2008)
- "Transcending Obamacare: A patient-centered plan for near-universal coverage and permanent fiscal solvency" (2014)[URL]
- "Healthcare reform law: Impact on pharmaceutical manufacturers" (2010)[URL]
- Spatz, I., "Health reform accelerates changes in the pharmaceutical industry", Health Affairs, 29(7), pp.1331~1336 (2010)
- "JCX-17-10" (2010)[URL]
- "Medicare drug discount"[URL]